your partner in preclinical research

Latest Posts

> 2020 Jun

Upcoming AACR Virtual Meeting II

We are pleased to announce that Urosphere will be presenting its unique Patient-Derived Xenograft (PDX) bank of prostate cancers at AACR Virtual Meeting II.  Poster #1668.  June 22 - 24, 2020 Virtual Meeting II Click to view our abstract and register to see the poster on June, 22nd! https://www.abstractsonline.com/pp8/#!/9045/presentation/4863

Read more

> 2020 May

Urosphere acquires Urolead creating a center of excellence in preclinical urology.

Last December, the company has acquired Urolead, a company dedicated to uro-oncology and particularly to the development of Patient-Derived Xenografts (PDX) models for kidney, bladder and prostate cancers. Urolead’s expertise and PDX Biobank reinforces Urosphere’s activities providing a full package of specifically relevant models in oncology, from cells to PDXs. "The acquisition of Urolead is an essential part of our development strategy aiming at offering a full package of drug discovery portfolio of services and capabilities in urology” said Dr. Philippe Lluel, CEO of Urosphere. "This is an exciting development for Urosphere as we continue to grow and meet the needs of our clients." The company broadens its portofolio of preclinical models and expands its offer from services, co-development of molecules to licensing of PDX models. For further information, please do not hesitate to contact us contact@urosphere.com

Read more

> 2019 Jun

Urosphere participe à la 7e édition des AFSSI Connexions les 2/3 juillet 2019 à Lyon

  Urosphere sera présente sur l’espace village AFSSI les 2 et 3 juillet 2019 à Lyon. N'hésitez pas à venir nous voir sur le stand.  

Read more

> 2019 May

Urosphere/ Urolead and Institut Curie will present their last results at the AACR meeting, Denver: Bladder Cancer: Transforming the Field.

    Fruit of a long term collaboration, Urosphere and its affiliate Urolead (Toulouse) and Institut Curie (Paris) will present a fully characterized biobank of PDXs from bladder cancers and its relevant use as a drug discovery platform. The results will be presented in poster session A, on Sunday, May 19th and in plenary session 5, on Monday, May 20th.
Title: Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of muscle-invasive bladder tumors.
Isabelle Bernard-Pierrot, Institut Curie, Paris, France, poster board number A24
Title: PDX and genetic mouse models for deciphering signaling pathways in bladder cancer.
François R. Radvanyi, Institut Curie, Paris, France, Plenary Session 5: Models for Discovery Please, do not hesitate to attend these sessions and contact us.    

Read more

> 2019 Mar

Urosphere will be present at the European Association of Urology congress 2019.


    Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019). Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues.  It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.

Read more